Sugammadex + Rocuronium

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anesthesia, General

Conditions

Anesthesia, General

Trial Timeline

Oct 27, 2005 → Sep 9, 2006

About Sugammadex + Rocuronium

Sugammadex + Rocuronium is a phase 3 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00475215. Target conditions include Anesthesia, General.

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT02484651ApprovedCompleted
NCT02451202ApprovedCompleted
NCT00656799Phase 3Completed
NCT00475215Phase 3Completed
NCT00298831Phase 3Completed

Competing Products

20 competing products in Anesthesia, General

See all competitors